{"organizations": [], "uuid": "52694782b8daccf4030d453026dc87e8754bccec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180518.html", "section_title": "Archive News &amp; Video for Friday, 18 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-valeritas-announces-positive-resul/brief-valeritas-announces-positive-results-from-studies-testing-cos-insulin-delivery-device-idUSFWN1SP0J9", "country": "US", "domain_rank": 408, "title": "BRIEF-Valeritas Announces Positive Results From Studies Testing Co's Insulin Delivery Device", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-18T21:01:00.000+03:00", "replies_count": 0, "uuid": "52694782b8daccf4030d453026dc87e8754bccec"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-valeritas-announces-positive-resul/brief-valeritas-announces-positive-results-from-studies-testing-cos-insulin-delivery-device-idUSFWN1SP0J9", "ord_in_thread": 0, "title": "BRIEF-Valeritas Announces Positive Results From Studies Testing Co's Insulin Delivery Device", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-valeritas announces positive results from studies testing co", "sentiment": "negative"}, {"name": "valeritas holdings inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18 (Reuters) - Valeritas Holdings Inc:\n* VALERITAS ANNOUNCES POSITIVE CLINICAL RESULTS ACROSS TWO NEW STUDIES EVALUATING V-GOÂ® WEARABLE INSULIN DELIVERY DEVICE IN PATIENTS WITH TYPE 2 DIABETES\n* VALERITAS HOLDINGS - IN TRIAL, AFTER THREE MONTHS OF V-GO USE, SIGNIFICANT REDUCTIONS WERE OBSERVED IN BOTH A1C AND TDD\n* VALERITAS HOLDINGS INC - IMPROVEMENTS IN A1C WERE NOTED ACROSS A WIDE RANGE OF BASELINE INSULIN DOSES IN TRIAL Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-18T21:01:00.000+03:00", "crawled": "2018-05-19T15:22:48.018+03:00", "highlightTitle": ""}